Developer docs
API playgroundTry for free, no card

Search company profiles

Kinaset Therapeutics

Full company profile

uuid0002deo

Namestring
Kinaset Therapeutics
Legal namestring
Kinaset Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Kinaset Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts. The company is focused exclusively on developing inhaled therapeutics for respiratory diseases, with a single lead asset, frevecitinib (KN-002), being advanced for the treatment of severe asthma and, on the basis of early Phase 1 data, with potential expansion into chronic obstructive pulmonary disease (COPD). Frevecitinib is a novel small-molecule inhibitor of all four JAK isoforms (JAK1, JAK2, JAK3, TYK2), formulated as a dry powder for delivery via a single-capsule dry powder inhaler. This pan-JAK inhaled approach is designed to deliver therapeutic drug concentrations directly to lung tissue while minimizing systemic exposure, and is positioned to treat both eosinophilic and non-eosinophilic severe asthma — the latter population being roughly half of all severe asthma patients who do not adequately respond to existing parenteral biologic therapies.

The company acquired worldwide rights to KN-002 (originally VR588) through an exclusive in-license from Vectura Group at its Series A launch. Since then, Kinaset has progressed through Phase 1/1b clinical evaluation, demonstrating clinically relevant reductions in fractional exhaled nitric oxide (FeNO) without safety or tolerability concerns at doses up to 16 mg, and has obtained FDA clearance of its IND application to initiate Phase 2b dose-ranging studies in patients with asthma inadequately controlled on standard inhaled corticosteroid/long-acting beta-agonist therapy. The senior leadership team — CEO Robert Clarke (ex-CEO Pulmatrix), CBO/COO Roger Heerman (ex-EVP Vectura), CDO Frazer Morgan (ex-VP Vectura), and CMO Christopher O'Brien (ex-Janssen, Teva, AstraZeneca) — combines decades of inhaled therapeutics development and respiratory clinical experience.

Kinaset's business model is pre-commercial: it is a venture-backed R&D organization with no approved products, no product revenue, and no commercial distribution infrastructure. The company has raised approximately $143 million across a $40 million Series A (November 2020) led by 5AM Ventures and Atlas Venture, an early $1.5 million round, and a $103 million oversubscribed Series B (January 2026) led by RA Capital Management and Forge Life Science Partners. Future revenue, if frevecitinib is approved, would be generated through prescription pharmaceutical sales (potentially via distribution partnerships) targeting the severe asthma patient population estimated at approximately 1.5–2 million globally.

Short descriptiontext

Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing frevecitinib (KN-002), an inhaled pan-JAK inhibitor delivered via single-capsule dry powder inhaler, targeting severe asthma patients (including non-eosinophilic subtypes) and potentially COPD. Founded 2020, Boston-based, pre-revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
inhaled therapeutics, pan-JAK inhibitor, severe asthma treatment, respiratory drug development, biopharmaceutical pipeline
Industry1 code
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inhaled Respiratory Therapeutics
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing frevecitinib (KN-002), a novel inhaled pan-JAK inhibitor formulated as a dry powder for delivery via a single-capsule dry powder inhaler. The product candidate is designed to deliver anti-inflammatory therapy directly to the lungs of patients with severe asthma (and potentially COPD), addressing both eosinophilic and non-eosinophilic phenotypes that are inadequately controlled on standard inhaled corticosteroid/LABA therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1b: Once- and twice-daily administration of KN-002 achieved clinically relevant reductions in fractional exhaled nitric oxide (FeNO) levels without safety concerns
+2 more records
Product overview1 text field

Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing a single lead product candidate, frevecitinib (KN-002), an inhaled pan-JAK inhibitor. The company is not a multi-product platform but rather focused on advancing this one novel therapeutic through clinical development for severe asthma and potentially COPD. The product is an inhaled dry powder formulation delivered via a single-capsule inhaler, targeting the broad severe asthma population including those with non-eosinophilic disease who lack effective treatment options.

Product and service1 record
1Frevecitinib (KN-002)
CategoryInhaled Respiratory Therapeutics
Description

Novel inhaled pan-JAK inhibitor (JAK1, JAK2, JAK3, TYK2) formulated as a dry powder for delivery via a single-capsule dry powder inhaler. Designed to deliver therapeutic anti-inflammatory drug concentrations directly to the lungs while minimizing systemic exposure, with the goal of treating severe asthma patients regardless of eosinophilic or non-eosinophilic phenotype and potentially COPD. Currently in clinical development with FDA IND clearance obtained for Phase 2b dose-ranging studies in asthma.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global biopharmaceutical company and co-developer of dupilumab (Dupixent) with Regeneron—the leading severe asthma biologic with broadest label. Broad incumbent with the dominant prescriber and payer footprint Kinaset would need to displace.

TypeBroad incumbent
Description

Global biopharmaceutical company with a major respiratory franchise including tezepelumab (Tezspire) for severe asthma, Fasenra, and Symbicort. Comparable as the broad incumbent setting the standard of care in severe asthma biologics.

TypeBroad incumbent
Description

Global biopharmaceutical company with a leading severe asthma biologic franchise including mepolizumab (Nucala) and benralizumab (Fasenra), as well as Trelegy for COPD. Broad incumbent competitor in the same therapeutic area.

TypeEmerging player
Description

European biotech with a historical respiratory franchise (filgotinib, a JAK1 inhibitor, was co-developed with Gilead for inflammatory diseases including potential respiratory indications). Comparable as a JAK-pathway developer with respiratory/immunology overlap, though no longer focused on inhaled delivery.

TypeDirect peer
Description

Clinical-stage biotech developing verekitug, an anti-TSLP antibody for severe asthma and other inflammatory respiratory diseases. Closely comparable development-stage respiratory company with biologic and now broader mechanism approaches.

TypeEmerging player
Description

Clinical-stage inhaled therapeutics company developing iSPERSE-based dry powder formulations for respiratory diseases including COPD and asthma. Comparable as a small inhaled-respiratory biotech; notably, Kinaset CEO Robert Clarke was previously CEO of Pulmatrix.

TypeDirect peer
Description

Clinical-stage inflammation and immunology company that has developed rademikibart (anti-IL-4Rα) for severe asthma and atopic dermatitis. Comparable as a development-stage immunology biotech pursuing severe asthma with a novel anti-inflammatory.

TypeEmerging player
Description

Clinical-stage immunology company focused on inflammatory diseases including respiratory indications. Comparable as a small-cap clinical-stage biotech pursuing anti-inflammatory mechanisms in respiratory/immunology.

TypeDirect peer
Description

Respiratory therapeutics company that developed ensifentrine (Ohtuvayre), the first inhaled PDE3/PDE4 inhibitor approved for COPD maintenance therapy in 2024. Closely comparable as an inhaled small-molecule respiratory therapeutic developer; acquired by Merck in 2025.

TypeDirect peer
Description

Clinical-stage biotech developing an oral DP2 antagonist (dexpramipexole) for severe eosinophilic asthma. Directly comparable as a Phase 2/3 respiratory-focused biotech targeting severe asthma with a differentiated mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kinaset Therapeutics

Inhaled Respiratory Therapeuticskinasettherapeutics.com

Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing frevecitinib (KN-002), an inhaled pan-JAK inhibitor delivered via single-capsule dry powder inhaler, targeting severe asthma patients (including non-eosinophilic subtypes) and potentially COPD. Founded 2020, Boston-based, pre-revenue.

What Kinaset Therapeutics does

Kinaset Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts. The company is focused exclusively on developing inhaled therapeutics for respiratory diseases, with a single lead asset, frevecitinib (KN-002), being advanced for the treatment of severe asthma and, on the basis of early Phase 1 data, with potential expansion into chronic obstructive pulmonary disease (COPD). Frevecitinib is a novel small-molecule inhibitor of all four JAK isoforms (JAK1, JAK2, JAK3, TYK2), formulated as a dry powder for delivery via a single-capsule dry powder inhaler. This pan-JAK inhaled approach is designed to deliver therapeutic drug concentrations directly to lung tissue while minimizing systemic exposure, and is positioned to treat both eosinophilic and non-eosinophilic severe asthma — the latter population being roughly half of all severe asthma patients who do not adequately respond to existing parenteral biologic therapies.

The company acquired worldwide rights to KN-002 (originally VR588) through an exclusive in-license from Vectura Group at its Series A launch. Since then, Kinaset has progressed through Phase 1/1b clinical evaluation, demonstrating clinically relevant reductions in fractional exhaled nitric oxide (FeNO) without safety or tolerability concerns at doses up to 16 mg, and has obtained FDA clearance of its IND application to initiate Phase 2b dose-ranging studies in patients with asthma inadequately controlled on standard inhaled corticosteroid/long-acting beta-agonist therapy. The senior leadership team — CEO Robert Clarke (ex-CEO Pulmatrix), CBO/COO Roger Heerman (ex-EVP Vectura), CDO Frazer Morgan (ex-VP Vectura), and CMO Christopher O'Brien (ex-Janssen, Teva, AstraZeneca) — combines decades of inhaled therapeutics development and respiratory clinical experience.

Kinaset's business model is pre-commercial: it is a venture-backed R&D organization with no approved products, no product revenue, and no commercial distribution infrastructure. The company has raised approximately $143 million across a $40 million Series A (November 2020) led by 5AM Ventures and Atlas Venture, an early $1.5 million round, and a $103 million oversubscribed Series B (January 2026) led by RA Capital Management and Forge Life Science Partners. Future revenue, if frevecitinib is approved, would be generated through prescription pharmaceutical sales (potentially via distribution partnerships) targeting the severe asthma patient population estimated at approximately 1.5–2 million globally.

Kinaset Therapeutics firmographics

Firmographics
Name
Kinaset Therapeutics
Legal name
Kinaset Therapeutics, Inc.
Website
https://kinasettherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing frevecitinib (KN-002), an inhaled pan-JAK inhibitor delivered via single-capsule dry powder inhaler, targeting severe asthma patients (including non-eosinophilic subtypes) and potentially COPD. Founded 2020, Boston-based, pre-revenue.
Ownership category
akta.pro rank

Kinaset Therapeutics industry classification

Industry
Product category
Inhaled Respiratory Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Inhaled therapeutics
  • Pan-JAK inhibitor
  • Severe asthma treatment
  • Respiratory drug development
  • Biopharmaceutical pipeline

Where Kinaset Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Kinaset Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels3 records

Kinaset Therapeutics product offering

Product offering

Core offering

Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing frevecitinib (KN-002), a novel inhaled pan-JAK inhibitor formulated as a dry powder for delivery via a single-capsule dry powder inhaler. The product candidate is designed to deliver anti-inflammatory therapy directly to the lungs of patients with severe asthma (and potentially COPD), addressing both eosinophilic and non-eosinophilic phenotypes that are inadequately controlled on standard inhaled corticosteroid/LABA therapy.

Product overview

Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing a single lead product candidate, frevecitinib (KN-002), an inhaled pan-JAK inhibitor. The company is not a multi-product platform but rather focused on advancing this one novel therapeutic through clinical development for severe asthma and potentially COPD. The product is an inhaled dry powder formulation delivered via a single-capsule inhaler, targeting the broad severe asthma population including those with non-eosinophilic disease who lack effective treatment options.

Differentiator

Problem solved

Functional benefit

Products and services

  • Frevecitinib (KN-002) Novel inhaled pan-JAK inhibitor (JAK1, JAK2, JAK3, TYK2) formulated as a dry powder for delivery via a single-capsule dry powder inhaler. Designed to deliver therapeutic anti-inflammatory drug concentrations directly to the lungs while minimizing systemic exposure, with the goal of treating severe asthma patients regardless of eosinophilic or non-eosinophilic phenotype and potentially COPD. Currently in clinical development with FDA IND clearance obtained for Phase 2b dose-ranging studies in asthma.

Quantifiable outcome

  • Phase 1b: Once- and twice-daily administration of KN-002 achieved clinically relevant reductions in fractional exhaled nitric oxide (FeNO) levels without safety concerns
  • +2 more outcomes

Companies that use Kinaset Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Kinaset Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kinaset Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

Kinaset Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Global biopharmaceutical company and co-developer of dupilumab (Dupixent) with Regeneron—the leading severe asthma biologic with broadest label. Broad incumbent with the dominant prescriber and payer footprint Kinaset would need to displace.
  • AstraZeneca: Global biopharmaceutical company with a major respiratory franchise including tezepelumab (Tezspire) for severe asthma, Fasenra, and Symbicort. Comparable as the broad incumbent setting the standard of care in severe asthma biologics.
  • GSK: Global biopharmaceutical company with a leading severe asthma biologic franchise including mepolizumab (Nucala) and benralizumab (Fasenra), as well as Trelegy for COPD. Broad incumbent competitor in the same therapeutic area.

Emerging players

  • Galapagos NV: European biotech with a historical respiratory franchise (filgotinib, a JAK1 inhibitor, was co-developed with Gilead for inflammatory diseases including potential respiratory indications). Comparable as a JAK-pathway developer with respiratory/immunology overlap, though no longer focused on inhaled delivery.
  • Pulmatrix: Clinical-stage inhaled therapeutics company developing iSPERSE-based dry powder formulations for respiratory diseases including COPD and asthma. Comparable as a small inhaled-respiratory biotech; notably, Kinaset CEO Robert Clarke was previously CEO of Pulmatrix.
  • Avalo Therapeutics: Clinical-stage immunology company focused on inflammatory diseases including respiratory indications. Comparable as a small-cap clinical-stage biotech pursuing anti-inflammatory mechanisms in respiratory/immunology.

Direct peers

  • Upstream Bio: Clinical-stage biotech developing verekitug, an anti-TSLP antibody for severe asthma and other inflammatory respiratory diseases. Closely comparable development-stage respiratory company with biologic and now broader mechanism approaches.
  • Connect Biopharma: Clinical-stage inflammation and immunology company that has developed rademikibart (anti-IL-4Rα) for severe asthma and atopic dermatitis. Comparable as a development-stage immunology biotech pursuing severe asthma with a novel anti-inflammatory.
  • Verona Pharma: Respiratory therapeutics company that developed ensifentrine (Ohtuvayre), the first inhaled PDE3/PDE4 inhibitor approved for COPD maintenance therapy in 2024. Closely comparable as an inhaled small-molecule respiratory therapeutic developer; acquired by Merck in 2025.
  • Areteia Therapeutics: Clinical-stage biotech developing an oral DP2 antagonist (dexpramipexole) for severe eosinophilic asthma. Directly comparable as a Phase 2/3 respiratory-focused biotech targeting severe asthma with a differentiated mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Kinaset Therapeutics social profiles

Digital presence

Kinaset Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kinaset Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Kinaset Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kinaset Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kinaset Therapeutics

What does Kinaset Therapeutics do?

Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing frevecitinib (KN-002), a novel inhaled pan-JAK inhibitor formulated as a dry powder for delivery via a single-capsule dry powder inhaler. The product candidate is designed to deliver anti-inflammatory therapy directly to the lungs of patients with severe asthma (and potentially COPD), addressing both eosinophilic and non-eosinophilic phenotypes that are inadequately controlled on standard inhaled corticosteroid/LABA therapy.

Is Kinaset Therapeutics a public or private company?

Kinaset Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kinaset Therapeutics founded?

Kinaset Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Kinaset Therapeutics based?

Kinaset Therapeutics is headquartered in Boston, United States, in the North America region.

Who are Kinaset Therapeutics's main competitors?

Broad incumbents on record are Sanofi, AstraZeneca and GSK. Emerging players are Galapagos NV, Pulmatrix and Avalo Therapeutics. Direct peers are Upstream Bio, Connect Biopharma, Verona Pharma and Areteia Therapeutics.

Does Kinaset Therapeutics have an API?

No public API is recorded for Kinaset Therapeutics.

What industry is Kinaset Therapeutics in?

Kinaset Therapeutics's product category is Inhaled Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceKinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe AsthmaKinaset Therapeutics announced the first patient has been dosed in its Phase 2b PANAIRAMA trial of frevecitinib, an inhaled pan-JAK inhibitor, for severe asthma inadequately controlled on medium-to-high dose ICS/LABA. The randomized, double-blind, placebo-controlled study will evaluate three doses to identify the optimal regimen for future pivotal development.Business Wire BlogKinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee ChairKinaset Therapeutics appointed Daniel G. Welch as board chair and David Lubner as independent director and audit committee chair. The appointments follow a $103 million Series B financing and support the Phase 2b trial of frevecitinib in severe asthma. Thomas B. King will step down as chair.openPR.comAsthma Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi PharmaDelveInsight published its Asthma Pipeline 2026 report outlining the global asthma drug development landscape, which comprises over 80 companies working on more than 90 treatment therapies across various stages of development. The US FDA approved GSK's Exdensur (depemokimab) in December 2025/February 2026 as the first ultra-long-acting biologic for severe eosinophilic asthma with twice-yearly dosing, and Areteia Therapeutics reported positive Phase III EXHALE-4 results for oral dexpramipexole in September 2025. AstraZeneca's Breztri Aerosphere met primary endpoints in two Phase III trials in May 2025, and the FDA approved the first generic version of Flovent HFA in March 2026.PR NewswireEQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseasesEQT Life Sciences announced that its LSP 7 Fund participated in Kinaset Therapeutics' oversubscribed USD 103 million Series B financing round, co-led by RA Capital Management and Forge Life Science Partners, with participation from multiple new and existing investors. The proceeds will advance frevecitinib, a novel inhaled pan-JAK inhibitor dry powder inhaler in development for patients with severe asthma inadequately controlled by standard therapies. Daniela Begolo, Managing Director at EQT Life Sciences, will join Kinaset Therapeutics' Board of Directors as part of this investment.FinSMEsKinaset Therapeutics Raises $103M in Series B FundingKinaset Therapeutics raised $103M in Series B funding led by RA Capital Management and Forge Life Science Partners. The company will use the funds to advance its inhaled pan-JAK inhibitor frevecitinib for asthma. New investors include EQT Life Sciences, Vivo Capital, and Schroders Capital.EuropaWireEQT Life Sciences Invests in Inhaled Asthma Therapy Developer Kinaset TherapeuticsEQT Life Sciences invested in Boston-based Kinaset Therapeutics as part of a USD 103 million oversubscribed Series B financing round to advance frevecitinib, a novel inhaled pan-JAK inhibitor for asthma treatment. The funding round was co-led by RA Capital Management and Forge Life Science Partners, with participation from multiple new and existing investors. Kinaset plans to use the proceeds to progress frevecitinib into a Phase 2 dose-ranging clinical study in patients with severe asthma.news.cision.comEQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseasesEQT Life Sciences announced participation in Kinaset Therapeutics' oversubscribed USD 103 million Series B financing round, joining a syndicate led by RA Capital Management and Forge Life Science Partners. The proceeds will advance frevecitinib, an inhaled pan-JAK inhibitor developed as a single-capsule dry powder inhaler for severe asthma patients inadequately controlled by existing therapies. Daniela Begolo, Managing Director at EQT Life Sciences, will join Kinaset Therapeutics' Board of Directors as part of the transaction.KinasettherapeuticsKinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases — Kinaset TherapeuticsKinaset Therapeutics closed a $103 million oversubscribed Series B financing round led by RA Capital Management and Forge Life Science Partners, with participation from EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital, and existing investors Atlas Venture, 5AM Ventures and Gimv. The proceeds will advance frevecitinib, the company's inhaled pan-JAK inhibitor, through Phase 2 dose-ranging clinical studies in patients with severe asthma. Three new board members from the lead investors joined Kinaset's board in conjunction with the financing.Pulse 2.0Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe AsthmaKinaset Therapeutics closed a $103 million oversubscribed Series B financing led by RA Capital Management and Forge Life Science Partners to advance its lead inhaled pan-JAK inhibitor frevecitinib through Phase 2 clinical studies for severe asthma. The round included participation from EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital, and existing investors Atlas Venture, 5AM Ventures, and Gimv. Frevecitinib is a novel dry-powder formulation designed to act directly in the lungs while limiting systemic exposure, targeting JAK1, JAK2, JAK3, and TYK2 to address both Th2- and Th1-driven inflammatory pathways, including non-eosinophilic asthma patients who have limited treatment options.Venture Capital Access OnlineKinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory DiseasesKinaset Therapeutics, a clinical-stage biopharmaceutical company, closed a $103 million oversubscribed Series B financing round led by RA Capital Management and Forge Life Science Partners, with participation from multiple new and existing investors. The proceeds will advance frevecitinib, a novel inhaled pan-JAK inhibitor for severe asthma, through Phase 2 dose-ranging clinical studies. Henry Stusnick from RA Capital Management, Daniela Begolo from EQT Life Sciences, and Peter B. Silverman from Forge Life Science Partners joined Kinaset's board of directors in conjunction with the financing.